- Home
- SUI vs UTHR Comparison
SUI vs UTHR Comparison
Compare SUI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUI
- UTHR
- Stock Information
- Founded
- SUI 1975
- UTHR 1996
- Country
- SUI United States
- UTHR United States
- Employees
- SUI N/A
- UTHR N/A
- Industry
- SUI Real Estate Investment Trusts
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- SUI Real Estate
- UTHR Health Care
- Exchange
- SUI Nasdaq
- UTHR Nasdaq
- Market Cap
- SUI 15.9B
- UTHR 13.8B
- IPO Year
- SUI 1993
- UTHR 1999
- Fundamental
- Price
- SUI $130.00
- UTHR $405.02
- Analyst Decision
- SUI Buy
- UTHR Strong Buy
- Analyst Count
- SUI 14
- UTHR 15
- Target Price
- SUI $138.21
- UTHR $449.13
- AVG Volume (30 Days)
- SUI 835.8K
- UTHR 902.7K
- Earning Date
- SUI 11-05-2025
- UTHR 10-29-2025
- Dividend Yield
- SUI 3.20%
- UTHR N/A
- EPS Growth
- SUI 1883.93
- UTHR 17.94
- EPS
- SUI 10.23
- UTHR 25.63
- Revenue
- SUI $3,217,100,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- SUI N/A
- UTHR $13.89
- Revenue Next Year
- SUI $4.21
- UTHR $5.68
- P/E Ratio
- SUI $12.92
- UTHR $15.80
- Revenue Growth
- SUI 17.94
- UTHR 17.62
- 52 Week Low
- SUI $109.22
- UTHR $266.98
- 52 Week High
- SUI $147.83
- UTHR $436.95
- Technical
- Relative Strength Index (RSI)
- SUI 57.54
- UTHR 71.35
- Support Level
- SUI $128.19
- UTHR $395.00
- Resistance Level
- SUI $130.97
- UTHR $401.62
- Average True Range (ATR)
- SUI 2.10
- UTHR 13.35
- MACD
- SUI 0.34
- UTHR 6.12
- Stochastic Oscillator
- SUI 75.65
- UTHR 76.31
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 502 properties, which includes 337 manufactured housing communities and 165 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.